HilleVax (NASDAQ:HLVX) Shares Gap Up to $12.02

HilleVax, Inc. (NASDAQ:HLVX) shares gapped up prior to trading on Friday . The stock had previously closed at $12.02, but opened at $12.58. HilleVax shares last traded at $11.99, with a volume of 1,768 shares.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of HilleVax in a research report on Thursday, March 21st.

HilleVax Stock Performance

The stock’s 50-day simple moving average is $15.84 and its two-hundred day simple moving average is $14.60. The stock has a market cap of $635.92 million, a price-to-earnings ratio of -4.21 and a beta of 0.65. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.62 and a current ratio of 10.62.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings data on Wednesday, March 20th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.02. Analysts forecast that HilleVax, Inc. will post -3.22 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Shane Maltbie sold 3,576 shares of HilleVax stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $14.93, for a total value of $53,389.68. Following the completion of the transaction, the chief financial officer now owns 40,656 shares of the company’s stock, valued at approximately $606,994.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Shane Maltbie sold 3,576 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total transaction of $53,389.68. Following the completion of the transaction, the chief financial officer now directly owns 40,656 shares in the company, valued at approximately $606,994.08. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Life Sciences X. L.P. Frazier acquired 8,850 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were bought at an average price of $14.50 per share, with a total value of $128,325.00. Following the completion of the transaction, the insider now owns 8,544,187 shares in the company, valued at $123,890,711.50. The disclosure for this purchase can be found here. Insiders have sold a total of 78,039 shares of company stock worth $986,464,242 over the last ninety days. Company insiders own 29.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HLVX. Catalys Pacific LLC purchased a new stake in HilleVax during the fourth quarter worth about $21,009,000. Franklin Resources Inc. increased its holdings in HilleVax by 4.1% during the fourth quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock worth $29,635,000 after buying an additional 71,938 shares during the last quarter. Swiss National Bank increased its holdings in HilleVax by 22.4% during the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after buying an additional 7,000 shares during the last quarter. abrdn plc purchased a new stake in HilleVax during the fourth quarter worth about $433,000. Finally, SG Americas Securities LLC purchased a new stake in HilleVax during the fourth quarter worth about $139,000. 86.42% of the stock is owned by institutional investors.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.